Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions.
Verheye S, Costa RA, Schofer J, Ormiston JA, Maeng M, Dudek D, Skurk C, Botelho RV, Costa JR, Chamié D, Abizaid AS, Boersma E, Abizaid AA. Verheye S, et al. Among authors: abizaid as. EuroIntervention. 2019 Oct 20;15(8):685-687. doi: 10.4244/EIJ-D-18-00292. EuroIntervention. 2019. PMID: 30530403 Free article. No abstract available.
Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, Botelho RV, Costa JR Jr, Chamié D, Abizaid AS, Castro JP, Morrison L, Toyloy S, Bhat V, Yan J, Verheye S. Abizaid A, et al. Among authors: abizaid as. JACC Cardiovasc Interv. 2016 Mar 28;9(6):565-74. doi: 10.1016/j.jcin.2015.12.004. JACC Cardiovasc Interv. 2016. PMID: 27013155 Free article. Clinical Trial.
A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. Verheye S, et al. Among authors: abizaid as. JACC Cardiovasc Interv. 2014 Jan;7(1):89-99. doi: 10.1016/j.jcin.2013.07.007. Epub 2013 Oct 16. JACC Cardiovasc Interv. 2014. PMID: 24139932 Free article. Clinical Trial.
Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial.
Costa RA, Abizaid A, Abizaid AS, Garcia del Blanco B, Berland J, Petrov I, Brenot P, van Guens RJ, Royer T, Rubino P, Lesiak M, Fajadet J; BIPAX Investigators. Costa RA, et al. Among authors: abizaid as. EuroIntervention. 2012 Mar;7(11):1301-9. doi: 10.4244/EIJV7I11A205. EuroIntervention. 2012. PMID: 22433193 Free article. Clinical Trial.
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators. Feres F, et al. Among authors: abizaid as. JAMA. 2013 Dec 18;310(23):2510-22. doi: 10.1001/jama.2013.282183. JAMA. 2013. PMID: 24177257 Clinical Trial.
Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis.
Feres F, Muñoz JS, Abizaid A, Albertal M, Mintz GS, Staico R, Centemero M, Mattos LA, Maldonado G, Tanajura LF, Chaves A, Pinto I, Abizaid AS, Seixas AC, Vaz VD, Sousa A, Sousa JE. Feres F, et al. Among authors: abizaid as. Am J Cardiol. 2005 Dec 15;96(12):1656-62. doi: 10.1016/j.amjcard.2005.07.081. Epub 2005 Oct 21. Am J Cardiol. 2005. PMID: 16360353
36 results